Klinik für Innere Medizin IHämatologie, Onkologie und Stammzelltransplantation

Duque-Afonso J, Rassner P, Walther K, Ihorst G, Wehr C, Marks R, Wäsch R, Bertz H, Köhler T, Frye BC, Stolz D, Zeiser R, Finke J, Maas-Bauer K. Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens. Bone Marrow Transplant. 2024 Sep 27. doi: 10.1038/s41409-024-02422-z. Epub ahead of print. PMID: 39333758.

Maas-Bauer K*, Stell AV*, Yan KL*, de Vega E*, Vinnakota JM*, Unger S, Núñez N, Norona J, Talvard-Balland N, Koßmann S, Schwan C, Miething C, Martens US, Shoumariyeh K, Nestor RP, Duquesne S, Hanke K, Rackiewicz M, Hu Z, El Khawanky N, Taromi S, Andrlova H, Faraidun H, Walter S, Pfeifer D, Follo M, Waldschmidt J, Melchinger W, Rassner M, Wehr C, Schmitt-Graeff A, Halbach S, Liao J, Häcker G, Brummer T, Dengjel J, Andrieux G, Grosse R, Tugues S, Blazar BR, Becher B, Boerries M, Zeiser R. ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease. Nat Commun. 2024 Jan 10;15(1):446. doi: 10.1038/s41467-024-44703-7. PMID: 38199985; PMCID: PMC10781952.

Apostolova P, Kreutmair S, Toffalori C, Punta M, Unger S, Burk AC, Wehr C, Maas-Bauer K, Melchinger W, Haring E, Hoefflin R, Shoumariyeh K, Hupfer V, Lauer EM, Duquesne S, Lowinus T, Gonzalo Núñez N, Alberti C, da Costa Pereira S, Merten CH, Power L, Weiss M, Böke C, Pfeifer D, Marks R, Bertz H, Wäsch R, Ihorst G, Gentner B, Duyster J, Boerries M, Andrieux G, Finke J, Becher B, Vago L, Zeiser R. Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation-Immune signature correlates with response. Br J Haematol. 2023 Oct;203(2):264-281. doi: 10.1111/bjh.19007. Epub 2023 Aug 4. PMID: 37539479.

Single-cell Transcriptomics Reveal Different Maturation Stages and Sublineages Commitment of Human Thymic Invariant Natural Killer T cells. 
Maas-Bauer K, Köhler N, Stell AV, Zwick M, Acharya S, Rensing-Ehl A, König C, Kroll J, Baker J, Koßmann S, Pradier A, Wang S, Docquier M, Lewis DB, Negrin RS, Simonetta F.
J Leukoc Biol. 2023 Sep 23:qiad113.
doi: 10.1093/jleuko/qiad113.
Online ahead of print. PMID: 37742056

Invariant Natural Killer T Cell Subsets Have Diverse Graft-Versus-Host-Disease-Preventing and Anti-Tumor Effects.
Kristina Maas-Bauer*, Juliane K. Lohmeyer*, Toshihito Hirai, Teresa Lopes Ramos, Furqan M. Fazal, Ulrike M. Litzenburger, Karthryn E. Yost, Jessoca V. Ribado, Neeraja Kambham, Arielle S. Wenokur, Po-Yu Lin, Maite Alvarez, Melissa Mavers, Jeanette Baker, Ami S. Bhatt, Howard Y. Chang, Federico Simonetta and Robert S. Negrin.
Blood. 2021 Sep 9;138(10):858-870.
doi: 10.1182/blood.2021010887. PMID: 34036317

Allogeneic CAR-invariant Natural Killer T Cells Exert Potent Antitumor Effects Through Host CD8 T Cell Cross-Priming.
Federico Simonetta, Juliane Lohmeyer, Toshihito Hirai, Kristina Maas-Bauer, Maite Alvarez, Arielle Wenokur, Jeanette Baker, Amin Aalipour, Xuhuai Ji, Samuel Haile, Crystal Mackall, and Robert Negrin.
Clin Cancer Res 2021 Aug 10.
Doi: 10.1158/1078-0432.CCR-21-1329.
Online ahead of print.

Activation of natural killer T cells enhances the function of regulatory T cell therapy in suppressing murine GvHD.
Toshihito Hirai, Federico Simonetta, Kristina Maas-Bauer, Mustafa Turkoz, Melissa Mavers, Jeanette Baker and Robert S Negrin.
Blood Adv. 2021 Jun 8;5(11):2528-2538.
doi:10.1182/bloodadvances.2020003272. PMID: 34100904

Ruxolitinib-ECP combination treatment for refractory severe chronic graft-versus-host disease.
Kristina Maas-Bauer*, Chrissoula Kiote-Schmidt*, Hartmut Bertz, Petya Apostolova, Ralph Wäsch, Gabriele Ihorst, Jürgen Finke, Robert Zeiser.
Bone Marrow Transplant. 2021 Apr;56(4):909-916.
doi: 10.1038/s41409-020-01122-8. Epub 2020 Nov 17

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder SK, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuk F, Ajib S, de Fontbrune FS, Na IK, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit GU, Kuball J, Flynn R, Ihorst G, Du J, Blazar BR, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N.
Leukemia. 2015 Oct;29(10):2062-8.

Inhibition of protein geranylgeranylation and farnesylation protects against graft-versus-host disease via effects on CD4 effector cells.
Hechinger AK*, Maas K* (Maas-Bauer K), Dürr C, Leonhardt F, Prinz G, Marks R, Gerlach U, Hofmann M, Fisch P, Finke J, Pircher H, Zeiser R.  
Haematologica. 2013 Jan; 98(1):31-40.